And the great aspect about the health claims in China is that they are cracking down heavily on labelling/advertising of health claims on most products including IF.
A2M have been very strategic in conducting large clinical trials in China to ensure they can make their health claims when the evidence is there. Their competitors will struggle to make any health differential health claims given they are all essentially the same product with some minor variations in nutritional additives. Many of the key nutritional additives are being mandated by the Chinese government as part of the registration process so there is little room for differentiation by competitors.
Media Updates, page-7
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.15 |
Change
0.015(0.24%) |
Mkt cap ! $4.442B | |||
| Open | High | Low | Value | Volume |
| $6.10 | $6.18 | $6.09 | $4.896M | 797.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 13455 | $6.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.15 | 28391 | 29 |
View Market Depth
| Last trade - 13.45pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.14 |
Change
0.015 ( 0.66 %) |
||||
| Open | High | Low | Volume | ||
| $6.10 | $6.18 | $6.10 | 1345829 | ||
| Last updated 14.06pm 08/05/2024 ? | |||||
| A2M (ASX) Chart |